Coolibar’s Generous Donation to the AIM at Melanoma Foundation
Sun Safety for Everyone Under the Sun A Gift of Protection and Style Coolibar, a company that specializes in producing…
Blog - Melanoma360
10/10/2024
Coolibar’s Generous Donation to the AIM at Melanoma Foundation
Sun Safety for Everyone Under the Sun A Gift of Protection and Style Coolibar, a company that specializes in producing…
|
10/10/2024
Fall 2024 Newsletter
As we transition into fall, I wanted to take a moment to share some highlights from this busy spring and…
|
10/10/2024
Surviving the Spotlight: From Melanoma to Filmmaking
In this compelling episode of “Surviving the Spotlight,” we sit down with Jessica Gilstrap, a melanoma survivor and independent filmmaker,…
|
10/08/2024
Nailing Down on the Ultraviolet Exposure Occurring During the Curing and Drying of a Manicure
by Mandi Murph, Director of Medical Education Introduction It’s a health risk many may not know exists – nail lamps.…
10/01/2024
Ways to Give: Monthly Giving
Sixth Article in a Series Are you familiar with The Supporters Guild, AIM’s Monthly Giving Program? It empowers you to…
|
09/24/2024
Social Awareness and Support Needed for Spouses of Patients Recently Diagnosed With Cancer
Understanding Emotional Distress After a Cancer Diagnosis For a patient recently diagnosed with cancer, mental or psychological distress is normal.…
09/20/2024
Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin
How much is enough? Exploring excisional margins for in situ melanoma When a patient with melanoma in situ has a…
|
09/15/2024
Long-term Results Continue to Show a Benefit with Nivolumab and Ipilimumab
There is good news for patients with melanoma who received immunotherapy. Survival results from a major clinical trial, CheckMate-067, show…
|
09/15/2024
Ten Years of Pembrolizumab Shows Sustained Results
There is good news for patients with advanced melanoma who received pembrolizumab. Results from a clinical trial after ten years…
|
09/15/2024
Oncolytic Virotherapy Shows Promise in Advanced Melanoma that Failed Immunotherapy
New clinical trial data shows that additional options may soon become available for patients with melanoma for whom immunotherapy did…
|
Recent Posts
Jun. 03, 2025
Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence
May. 28, 2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
May. 14, 2025
Parenting Through Cancer
May. 09, 2025
Tri-State Melanoma Consortium – Inaugural Convening
May. 01, 2025